Cowen analyst, Boris Peaker, reiterated his Outperform rating on shares of Jounce Therapeutics (NASDAQ: JNCE), after the company announced the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE